L M Dember

Summary

Affiliation: Boston University
Country: USA

Publications

  1. ncbi request reprint Case records of the Massachusetts General Hospital. Case 15-2005. An 80-year-old man with shortness of breath, edema, and proteinuria
    Laura M Dember
    Renal Section, Department of Medicine, Boston Medical Center, Boston University School of Medicine, Boston, USA
    N Engl J Med 352:2111-9. 2005
  2. ncbi request reprint Light chains, casts, sheets and fibrils: monoclonal immunoglobulin diseases and immunotactoid/fibrillary glomerulopathy
    Laura M Dember
    Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    Clin J Am Soc Nephrol 1:1320-1. 2006
  3. ncbi request reprint Eprodisate for the treatment of renal disease in AA amyloidosis
    Laura M Dember
    Boston University School of Medicine, Boston, MA 02118, USA
    N Engl J Med 356:2349-60. 2007
  4. ncbi request reprint Dialysis-related amyloidosis: late finding or hidden epidemic?
    Laura M Dember
    Renal Section, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Semin Dial 19:105-9. 2006
  5. ncbi request reprint Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial
    Laura M Dember
    Renal Section, Boston University School of Medicine, MA 02118 USA
    Clin Trials 2:413-22. 2005
  6. doi request reprint Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial
    Laura M Dember
    Boston University, School of Medicine, Renal Section, EBRC 504, 650 Albany St, Boston, Massachusetts 02118, USA
    JAMA 299:2164-71. 2008
  7. ncbi request reprint Critical care issues in the patient with chronic renal failure
    Laura M Dember
    Boston University School of Medicine, Renal Section, Evans Biomedical Research Center, 5th Floor, 650 Albany Street, Boston, MA 02465, USA
    Crit Care Clin 18:421-40. 2002
  8. ncbi request reprint Value of static venous pressure for predicting arteriovenous graft thrombosis
    Laura M Dember
    Renal Sections, Boston University School of Medicine and VA Boston Healthcare System, Boston, Massachusetts, USA
    Kidney Int 61:1899-904. 2002
  9. ncbi request reprint Modern treatment of amyloidosis: unresolved questions
    Laura M Dember
    Renal Section, Boston University School of Medicine, Boston, MA 02118, USA
    J Am Soc Nephrol 20:469-72. 2009
  10. ncbi request reprint Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease
    L M Dember
    Renal Section, EBRC 504, Boston University Medical Center, 650 Albany Street, Boston, MA 02118, USA
    Ann Intern Med 134:746-53. 2001

Research Grants

  1. Dialysis Access Consortium Clinical Trials
    LAURA DEMBER; Fiscal Year: 2006
  2. Determinants of Hemodialysis AV Fistula Maturation
    LAURA DEMBER; Fiscal Year: 2008

Detail Information

Publications30

  1. ncbi request reprint Case records of the Massachusetts General Hospital. Case 15-2005. An 80-year-old man with shortness of breath, edema, and proteinuria
    Laura M Dember
    Renal Section, Department of Medicine, Boston Medical Center, Boston University School of Medicine, Boston, USA
    N Engl J Med 352:2111-9. 2005
  2. ncbi request reprint Light chains, casts, sheets and fibrils: monoclonal immunoglobulin diseases and immunotactoid/fibrillary glomerulopathy
    Laura M Dember
    Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    Clin J Am Soc Nephrol 1:1320-1. 2006
  3. ncbi request reprint Eprodisate for the treatment of renal disease in AA amyloidosis
    Laura M Dember
    Boston University School of Medicine, Boston, MA 02118, USA
    N Engl J Med 356:2349-60. 2007
    ....
  4. ncbi request reprint Dialysis-related amyloidosis: late finding or hidden epidemic?
    Laura M Dember
    Renal Section, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Semin Dial 19:105-9. 2006
    ....
  5. ncbi request reprint Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial
    Laura M Dember
    Renal Section, Boston University School of Medicine, MA 02118 USA
    Clin Trials 2:413-22. 2005
    ..The autogenous arteriovenous fistula created by direct connection of native artery to vein is the recommended vascular access for hemodialysis. However, it fails frequently due to clotting after surgery...
  6. doi request reprint Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial
    Laura M Dember
    Boston University, School of Medicine, Renal Section, EBRC 504, 650 Albany St, Boston, Massachusetts 02118, USA
    JAMA 299:2164-71. 2008
    ..Small, inconclusive trials have suggested that antiplatelet agents may reduce thrombosis of new fistulas...
  7. ncbi request reprint Critical care issues in the patient with chronic renal failure
    Laura M Dember
    Boston University School of Medicine, Renal Section, Evans Biomedical Research Center, 5th Floor, 650 Albany Street, Boston, MA 02465, USA
    Crit Care Clin 18:421-40. 2002
    ..The recognition of ESRD as a state of chronic inflammation and increased oxidative stress ultimately should lead to more effective treatment approaches for several of the comorbid conditions common in this patient population...
  8. ncbi request reprint Value of static venous pressure for predicting arteriovenous graft thrombosis
    Laura M Dember
    Renal Sections, Boston University School of Medicine and VA Boston Healthcare System, Boston, Massachusetts, USA
    Kidney Int 61:1899-904. 2002
    ..However, it is not known how well static venous pressure elevation predicts subsequent AV graft thrombosis...
  9. ncbi request reprint Modern treatment of amyloidosis: unresolved questions
    Laura M Dember
    Renal Section, Boston University School of Medicine, Boston, MA 02118, USA
    J Am Soc Nephrol 20:469-72. 2009
    ..Additionally, observations from a clinical trial in AA amyloidosis have generated hypotheses about the relative contributions of amyloid precursors and mature fibrils to amyloidosis-associated kidney disease...
  10. ncbi request reprint Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease
    L M Dember
    Renal Section, EBRC 504, Boston University Medical Center, 650 Albany Street, Boston, MA 02118, USA
    Ann Intern Med 134:746-53. 2001
    ..The impact of this treatment on associated renal disease is not known...
  11. ncbi request reprint Amyloidosis-associated kidney disease
    Laura M Dember
    Renal Section, Boston University School of Medicine, EBRC 504, 650 Albany Street, Boston, MA 02118, USA
    J Am Soc Nephrol 17:3458-71. 2006
    ..This article reviews the pathogenesis, diagnosis, clinical manifestations, and treatment of the amyloidoses, focusing heavily on the renal aspects of each of these areas...
  12. ncbi request reprint An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis
    V Sanchorawala
    Stem Cell Transplant Program of the Section of Hematology and Oncology, Medical Center, Boston University School of Medicine, 88 East Newton Street, Boston, MA 02118, USA
    Bone Marrow Transplant 28:637-42. 2001
    ....
  13. ncbi request reprint Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis
    R L Comenzo
    Department of Medicine, Stem Cell Transplant Program, Boston Medical Center and Boston University School of Medicine, Massachusetts 02118, USA
    Br J Haematol 104:553-9. 1999
    ..The 100 d mortality was 20%. In conclusion, no definitive differences were identified between the mobilization regimens and IDM was an active regimen in AL for selected patients...
  14. ncbi request reprint High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial
    V Sanchorawala
    Hematology and Stem Cell Transplant Programs, Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA
    Bone Marrow Transplant 33:381-8. 2004
    ....
  15. ncbi request reprint Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation
    K Weichman
    Section of Hematology Oncology, Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA
    Bone Marrow Transplant 38:339-43. 2006
    ..In our experience, HDM/SCT is a feasible and effective treatment approach for these disorders...
  16. ncbi request reprint High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease
    Liam F Casserly
    Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Kidney Int 63:1051-7. 2003
    ..The efficacy and tolerability of such treatment for patients with AL amyloidosis-associated ESRD are unknown...
  17. ncbi request reprint Randomized controlled trial of prophylactic repair of hemodialysis arteriovenous graft stenosis
    Laura M Dember
    Renal Sections of Boston University School of Medicine, Boston, Massachusetts, USA
    Kidney Int 66:390-8. 2004
    ..The present study is a randomized trial comparing prophylactic repair of AV graft stenosis with repair at the time of thrombosis...
  18. ncbi request reprint Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis
    David C Seldin
    Boston University Medical Center, Boston Medical Center, MA, USA
    Clin Lymphoma 3:241-6. 2003
    ..No complete hematologic responses were seen, but 25% of patients had a significant reduction in Bence-Jones proteinuria. Thus, while thalidomide has activity in AL amyloidosis, it also has significant toxicity in this patient population...
  19. ncbi request reprint Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation
    David C Seldin
    Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
    Blood 104:1888-93. 2004
    ..Thus, treatment of AL amyloidosis patients with HDM/SCT produces measurable and sustained improvements in quality of life, particularly in those patients who achieve hematologic CR...
  20. ncbi request reprint High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study
    Martha Skinner
    Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Ann Intern Med 140:85-93. 2004
    ..AL amyloidosis is a fatal disease resulting from tissue deposition of amyloid fibrils derived from monoclonal immunoglobulin light chains. Treatment with oral chemotherapy is minimally effective...
  21. ncbi request reprint Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis
    John L Berk
    Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
    Chest 124:969-77. 2003
    ..We hypothesized that disruption of pleural function by amyloid deposits underlies persistent pleural effusions (PPEs) in patients with AL disease...
  22. ncbi request reprint Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis
    Vaishali Sanchorawala
    Department of Medicine, Section of Hematology Oncology, Boston Medical Center, Boston University School of Medicine, 88 East Newton Street, Boston, MA 02118, USA
    Br J Haematol 117:886-9. 2002
    ..This regimen appeared to be effective in inducing haematological responses in patients who received total doses of melphalan > 300 mg...
  23. ncbi request reprint Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis
    Amit Fadia
    The Renal Section, Stem Cell Transplant Program of the Hematology Oncology Section, and Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA
    Kidney Int 63:1868-73. 2003
    ..The incidence and outcome of ARF as a complication of such treatment is not known...
  24. ncbi request reprint Thrombosis in end-stage renal disease
    Liam F Casserly
    Renal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Semin Dial 16:245-56. 2003
    ..In this article we review the pathogenesis and clinical manifestations of thrombosis in ESRD and evaluate the evidence that chronic renal failure or its management predisposes to thrombotic events...
  25. ncbi request reprint MRI isolation of infected renal cyst in autosomal dominant polycystic kidney disease
    C Chicoskie
    Department of Radiology, Boston Medical Center, 88 East Newton Street, Boston, MA 02118, USA
    Clin Imaging 25:114-7. 2001
    ..We suggest that gadolinium-enhanced MR be considered useful in the evaluation of ADPKD patients with suspected infected cyst...
  26. pmc Kidney dysfunction during lenalidomide treatment for AL amyloidosis
    Richard Specter
    Renal Section, Boston University School of Medicine, Boston, MA, USA
    Nephrol Dial Transplant 26:881-6. 2011
    ..The objective of this study is to characterize alterations in kidney function among patients with AL amyloidosis undergoing treatment with lenalidomide...
  27. ncbi request reprint Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis
    Harun Akar
    Amyloid Treatment and Research Program at Boston Medical Center, Boston University School of Medicine, Boston, MA, 02118, USA
    Amyloid 12:210-5. 2005
    ..After a histologic tissue diagnosis of amyloidosis, determining the type as AL amyloidosis relies on a panel of hematologic tests to determine light chain clonality and the exclusion other forms of amyloidosis...
  28. ncbi request reprint Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial
    Bradley S Dixon
    Nephrology Division, Veterans Affairs Medical Center and University of Iowa School of Medicine, Iowa City 52242 1081, USA
    Clin Trials 2:400-12. 2005
    ..The Dialysis Access Consortium (DAC) Aggrenox Prevention of Access Stenosis Trial tests the hypothesis that Aggrenox (containing dipyridamole and aspirin) can prevent stenosis and prolong survival of arteriovenous grafts...
  29. ncbi request reprint Early fistula failure: back to basics
    Laura M Dember
    Am J Kidney Dis 50:696-9. 2007
  30. ncbi request reprint Emerging treatment approaches for the systemic amyloidoses
    Laura M Dember
    Kidney Int 68:1377-90. 2005

Research Grants2

  1. Dialysis Access Consortium Clinical Trials
    LAURA DEMBER; Fiscal Year: 2006
    ....
  2. Determinants of Hemodialysis AV Fistula Maturation
    LAURA DEMBER; Fiscal Year: 2008
    ....